Phase | Analysis | Cohort | Control | Cancer | AUC (95% CI) | Accuracya | PPVa | Sensitivitya | Specificitya | NPV |
---|---|---|---|---|---|---|---|---|---|---|
Tissue phase |  | Discovery cohort | 9 | 8 | 1 (1.00–1.00) | 1 (1.00–1.00) | 1 (1.00–1.00) | 1 (1.00–1.00) | 1 (1.00–1.00) | 1 (1.00–1.00) |
 | Validation cohort | 28 | 28 | 0.94 (0.88–1.00) | 0.88 (0.79–0.95) | 1 (1.00–1.00) | 0.75 (0.57–0.89) | 1 (1.00–1.00) | 0.8 (0.70–0.90) | |
Serum phase | Training | All GC vs controls | 46 | 92 | 0.87 (0.82–0.93) | 0.78 (0.71–0.85) | 0.88 (0.82–0.94) | 0.78 (0.70–0.87) | 0.78 (0.65–0.89) | 0.64 (0.55–0.75) |
Early- stage GC vs controls | 46 | 68 | 0.87 (0.80–0.93) | 0.77 (0.69–0.84) | 0.84 (0.77–0.92) | 0.76 (0.66–0.87) | 0.78 (0.65–0.89) | 0.69 (0.60–0.80) | ||
Diffuse GC vs controls | 46 | 45 | 0.85 (0.77–0.92) | 0.75 (0.66–0.84) | 0.69 (0.61–0.78) | 0.89 (0.80–0.98) | 0.61 (0.48–0.76) | 0.85 (0.74–0.96) | ||
Intestinal GC vs controls | 46 | 47 | 0.9 (0.84–0.96) | 0.82 (0.74–0.89) | 0.82 (0.73–0.91) | 0.83 (0.70–0.94) | 0.8 (0.70–0.91) | 0.83 (0.73–0.93) | ||
Validation | All GC vs controls | 48 | 102 | 0.83 (0.77–0.90) | 0.81 (0.75–0.87) | 0.83 (0.79–0.89) | 0.89 (0.83–0.95) | 0.62 (0.48–0.75) | 0.73 (0.62–0.85) | |
Early- stage GC vs controls | 48 | 69 | 0.82 (0.74–0.89) | 0.78 (0.71–0.85) | 0.77 (0.70–0.83) | 0.9 (0.83–0.96) | 0.6 (0.46–0.73) | 0.81 (0.69–0.92) | ||
Diffuse GC vs controls | 48 | 49 | 0.84 (0.77–0.92) | 0.78 (0.71–0.86) | 0.91 (0.82–1.00) | 0.63 (0.49–0.78) | 0.94 (0.85–1.00) | 0.71 (0.64–0.80) | ||
Intestinal GC vs controls | 48 | 53 | 0.83 (0.75–0.91) | 0.78 (0.70–0.85) | 0.73 (0.67–0.81) | 0.92 (0.85–0.98) | 0.62 (0.50–0.75) | 0.89 (0.78–0.97) |